Childhood Cancer - Seeing Gold Through the Pink

Cancer. The word alone makes us shift in discomfort and compels us to immediately redirect our thoughts away, towards words and thoughts that strike less fear, unless…. Unless cancer has become more than a word on our tongues and in our lives.

Cancer. Child. Childhood Cancer. The absolute worst modifier I can think of for that dreaded word “cancer.” And yet, it is the modifier that together with “cancer” represents the reality of approximately 12,400 children and their families each year in the U.S. Today, cancer is the most common cause of death by disease for children and adolescents in the U.S.

September is Childhood Cancer Awareness Month. The ribbon color is GOLD. How many gold ribbons have you seen? They are difficult to see through all the Pink so spread the word. No one wants or deserves cancer, least of all our precious children.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap